Cigna on July 10 said it will add three new Humira biosimilars — Boehringer Ingelheim’s Cyltezo and Sandoz’s Hyrimoz and Adalimumab-adaz (the unbranded equivalent of Hyrimoz) — to its national preferred, standard, performance, and legacy commercial formularies controlled by Cigna Pharmacy Management. The products will be preferred at parity with Humira. The company also said it will cover Organon’s Hadlima as a preferred drug on its value, advantage, and total savings formularies. Cigna Pharmacy Management, which handles drug benefits for Cigna Healthcare, currently manages 11.2 million pharmacy lives. Humira is a preferred product that requires utilization management, such as step therapy and/or prior authorization, for 67% of Cigna’s pharmacy lives.
SOURCE: MMIT Analytics, as of 7/12/23